213 related articles for article (PubMed ID: 31142513)
1. The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.
Krysan K; Tran LM; Grimes BS; Fishbein GA; Seki A; Gardner BK; Walser TC; Salehi-Rad R; Yanagawa J; Lee JM; Sharma S; Aberle DR; Spira AE; Elashoff DA; Wallace WD; Fishbein MC; Dubinett SM
Cancer Res; 2019 Oct; 79(19):5022-5033. PubMed ID: 31142513
[TBL] [Abstract][Full Text] [Related]
2. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
Chang K; Taggart MW; Reyes-Uribe L; Borras E; Riquelme E; Barnett RM; Leoni G; San Lucas FA; Catanese MT; Mori F; Diodoro MG; You YN; Hawk ET; Roszik J; Scheet P; Kopetz S; Nicosia A; Scarselli E; Lynch PM; McAllister F; Vilar E
JAMA Oncol; 2018 Aug; 4(8):1085-1092. PubMed ID: 29710228
[TBL] [Abstract][Full Text] [Related]
3. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.
Sivakumar S; Lucas FAS; McDowell TL; Lang W; Xu L; Fujimoto J; Zhang J; Futreal PA; Fukuoka J; Yatabe Y; Dubinett SM; Spira AE; Fowler J; Hawk ET; Wistuba II; Scheet P; Kadara H
Cancer Res; 2017 Nov; 77(22):6119-6130. PubMed ID: 28951454
[TBL] [Abstract][Full Text] [Related]
4. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung.
Sivakumar S; San Lucas FA; Jakubek YA; McDowell TL; Lang W; Kallsen N; Peyton S; Davies GE; Fukuoka J; Yatabe Y; Zhang J; Futreal PA; Fowler J; Fujimoto J; Ehli EA; Hawk ET; Wistuba II; Kadara H; Scheet P
EBioMedicine; 2019 Apr; 42():296-303. PubMed ID: 30905849
[TBL] [Abstract][Full Text] [Related]
5. Sequencing the Events That Mediate Progression of Premalignant Lung Lesions.
Merrick DT
Cancer Res; 2019 Oct; 79(19):4811-4813. PubMed ID: 31575628
[TBL] [Abstract][Full Text] [Related]
6. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas.
Hu X; Estecio MR; Chen R; Reuben A; Wang L; Fujimoto J; Carrot-Zhang J; McGranahan N; Ying L; Fukuoka J; Chow CW; Pham HHN; Godoy MCB; Carter BW; Behrens C; Zhang J; Antonoff MB; Sepesi B; Lu Y; Pass HI; Kadara H; Scheet P; Vaporciyan AA; Heymach JV; Wistuba II; Lee JJ; Futreal PA; Su D; Issa JJ; Zhang J
Nat Commun; 2021 Jan; 12(1):687. PubMed ID: 33514726
[TBL] [Abstract][Full Text] [Related]
7. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.
Zhang C; Zhang J; Xu FP; Wang YG; Xie Z; Su J; Dong S; Nie Q; Shao Y; Zhou Q; Yang JJ; Yang XN; Zhang XC; Li Z; Wu YL; Zhong WZ
J Thorac Oncol; 2019 Nov; 14(11):1912-1923. PubMed ID: 31446140
[TBL] [Abstract][Full Text] [Related]
8. The Adaptive Immune Landscape of the Colorectal Adenoma-Carcinoma Sequence.
Freitas JA; Gullo I; Garcia D; Miranda S; Spaans L; Pinho L; Reis J; Sousa F; Baptista M; Resende C; Leitão D; Durães C; Costa JL; Carneiro F; Machado JC
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575971
[TBL] [Abstract][Full Text] [Related]
9. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.
Sakamoto H; Shimizu J; Horio Y; Ueda R; Takahashi T; Mitsudomi T; Yatabe Y
J Pathol; 2007 Jul; 212(3):287-94. PubMed ID: 17534846
[TBL] [Abstract][Full Text] [Related]
10. Immunosurveillance and Regression in the Context of Squamous Pulmonary Premalignancy.
Krysan K; Tran LM; Dubinett SM
Cancer Discov; 2020 Oct; 10(10):1442-1444. PubMed ID: 33004476
[TBL] [Abstract][Full Text] [Related]
11. Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ.
Xu X; Li N; Zhao R; Zhu L; Shao J; Zhang J
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2447-2453. PubMed ID: 28821955
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
13. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.
Huynh TG; Morales-Oyarvide V; Campo MJ; Gainor JF; Bozkurtlar E; Uruga H; Zhao L; Gomez-Caraballo M; Hata AN; Mark EJ; Lanuti M; Engelman JA; Mino-Kenudson M
J Thorac Oncol; 2016 Nov; 11(11):1869-1878. PubMed ID: 27568346
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.
Lou Y; Diao L; Cuentas ER; Denning WL; Chen L; Fan YH; Byers LA; Wang J; Papadimitrakopoulou VA; Behrens C; Rodriguez JC; Hwu P; Wistuba II; Heymach JV; Gibbons DL
Clin Cancer Res; 2016 Jul; 22(14):3630-42. PubMed ID: 26851185
[TBL] [Abstract][Full Text] [Related]
15. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features.
Dejima H; Hu X; Chen R; Zhang J; Fujimoto J; Parra ER; Haymaker C; Hubert SM; Duose D; Solis LM; Su D; Fukuoka J; Tabata K; Pham HHN; Mcgranahan N; Zhang B; Ye J; Ying L; Little L; Gumbs C; Chow CW; Estecio MR; Godoy MCB; Antonoff MB; Sepesi B; Pass HI; Behrens C; Zhang J; Vaporciyan AA; Heymach JV; Scheet P; Lee JJ; Wu J; Futreal PA; Reuben A; Kadara H; Wistuba II; Zhang J
Nat Commun; 2021 May; 12(1):2722. PubMed ID: 33976164
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung.
Licchesi JD; Westra WH; Hooker CM; Herman JG
Clin Cancer Res; 2008 May; 14(9):2570-8. PubMed ID: 18451218
[TBL] [Abstract][Full Text] [Related]
17. Leveraging premalignant biology for immune-based cancer prevention.
Spira A; Disis ML; Schiller JT; Vilar E; Rebbeck TR; Bejar R; Ideker T; Arts J; Yurgelun MB; Mesirov JP; Rao A; Garber J; Jaffee EM; Lippman SM
Proc Natl Acad Sci U S A; 2016 Sep; 113(39):10750-8. PubMed ID: 27638202
[TBL] [Abstract][Full Text] [Related]
18. Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.
Saab S; Zalzale H; Rahal Z; Khalifeh Y; Sinjab A; Kadara H
Front Immunol; 2020; 11():159. PubMed ID: 32117295
[TBL] [Abstract][Full Text] [Related]
19. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
20. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
Sartori G; Cavazza A; Bertolini F; Longo L; Marchioni A; Costantini M; Barbieri F; Migaldi M; Rossi G
Am J Clin Pathol; 2008 Feb; 129(2):202-10. PubMed ID: 18208799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
